View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
  2. AI and automation
May 21, 2019updated 22 May 2019 1:35pm

AI Outperforms Radiologists in Lung Cancer Hunt – Google to Commercialise Model

Google aims to serve the model through its Cloud Healthcare API

By CBR Staff Writer

Researchers from Google and Stanford University have developed a machine learning model that shows huge potential to catch lung cancer cases early, outperforming the assessments of six radiologists – catching more cases and reducing false positives – after being trained on a dataset of 45,856 chest screens.

The model – detailed this week in a paper in the journal Nature Medicine, detected five percent more cancer cases while reducing false-positive exams by more than 11 percent compared to unassisted radiologists; achieving 94.4 percent accuracy when tested on 6,716 cases. Google said it aims to commercialise the model via its Cloud Healthcare API, which it released in April.

The research team, which also included participants from New York University-Lagone Medical Center, Northwestern Medicine, and Palo Alto Veterans Affairs, trained Tensorflow on three publicly available datasets and one proprietary one from Northwestern Medicine for the paper.

The result: a convolutional neural network model that can not only generate the overall lung cancer malignancy prediction, but also identify subtle malignant tissue in the lungs (lung nodules). The model can also factor in information from previous scans, useful in predicting lung cancer risk, as the growth rate of suspicious lung nodules can be indicative of malignancy, Google noted in an accompanying blog.

Content from our partners
Scan and deliver
GenAI cybersecurity: "A super-human analyst, with a brain the size of a planet."
Cloud, AI, and cyber security – highlights from DTX Manchester

Google technical lead Shravya Shetty, said: “Radiologists typically look through hundreds of 2D images within a single CT scan and cancer can be miniscule and hard to spot. We created a model that can not only generate the overall lung cancer malignancy prediction (viewed in 3D volume) but also identify subtle malignant tissue in the lungs (lung nodules). The model can also factor in information from previous scans, useful in predicting lung cancer risk because the growth rate of suspicious lung nodules can be indicative of malignancy.”

She added: “These initial results are encouraging, but further studies will assess the impact and utility in clinical practice. We’re collaborating with Google Cloud Healthcare and Life Sciences team to serve this model through the Cloud Healthcare API and are in early conversations with partners around the world to continue additional clinical validation research and deployment.”

Google is not releasing the code used for training the models, saying it “has a large number of dependencies on internal tooling, infrastructure and hardware, and its release is therefore not feasible.”

The researchers added, however: “All experiments and implementation details are described in sufficient detail in the Methods section to allow independent replication with non-proprietary libraries.” Several major components of the work are available in open source repositories, they added, pointing to the public datasets, along with the Tensorflow machine learning tool and its Object Detection API.

Read this: Google Cloud’s Healthcare API Aims to Tackle Interoperability Issues with Existing, Emerging Data Standards

Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
THANK YOU